Compare Amylx Pharmaceuticals Inc (AMLX) vs Beyond Meat Inc (BYND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Beyond Meat Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Beyond Meat Inc trades at $0.66 (market cap $338.06M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 5.9× Beyond Meat Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | BYND | |
|---|---|---|
Market Cap | $1.98B | $338.06M |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $4.28 |
52-Week Low | $7.64 | $0.52 |
Enterprise Value | $1.70B | $648.06M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
BYND trades at $0.656, down 2.77% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a net income margin of 79.49% but negative operating cash flow of -$144.93M in 2025. Recent product expansions include Beyond Steak Filet at Meijer and Wegmans, while earnings have been volatile with two misses and one beat in the last four quarters.
The outlook remains challenging with 57% analyst sell ratings and declining revenue trends. Key risks include persistent cash burn and competitive pressures. Upside potential hinges on successful turnaround efforts through new product launches and cost management, but the stock faces significant headwinds near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
